At meeting held on 27 February 2021
The Board of Aurobindo Pharma at its meeting held on 27 February 2021 has approved the following -1. Transfer of all equity shares held in Lyfius Pharma, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics, another wholly owned subsidiary of the Company.
2. Transfer of all equity shares held in Qule Pharma, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics, another wholly owned subsidiary of the Company.
3. Transfer of business undertaking comprised in Unit-10, on a going concern basis, to APL Healthcare, a wholly owned subsidiary of the Company.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU